<DOC>
	<DOCNO>NCT01290042</DOCNO>
	<brief_summary>To assess safety tolerability multiple subcutaneous dos AMG 181 healthy subject , subject active ulcerative colitis , subject active Crohn 's disease .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics AMG 181 .</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 34 kg/m2 Normal physical neurological examination , clinical laboratory value ECG Ulcerative Colitis Disease Activity Index ( UCDAI , aka Mayo score ) score 4 10 ( inclusive ) , minimum sigmoidoscopy score 1 ; ( subject ulcerative colitis ) Crohn 's Disease Activity Index ( CDAI ) score &gt; 150 &lt; 450 screening ( subject Crohn 's disease ) Additional inclusion criterion apply History evidence clinically significant disorder ( include psychiatric ) , condition disease would pose risk subject safety interfere study evaluation , procedure completion History malignancy type , situ cervical cancer surgically excise nonmelanomatous skin cancer within past 5 year Underlying condition ( ) predispose subject infection Disease limit rectum , i.e . within 10 cm anal verge ( subject ulcerative colitis ) Evidence severe disease ( evidence Hb concentration less equal 10g/dL ; toxic megacolon , UCDAI score great 10 ) ( subject ulcerative colitis ) Subject short bowel syndrome ( subject Crohn 's disease ) Presence ostomy ( subject Crohn 's disease ) Presence fistula ( subject Crohn 's disease ) Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>